More signs of trouble for Bayer and J&J's Xarelto? As prescriptions flag, the drugmakers blame stepped-up discounts for its U.S. sales woes.

Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all its therapy areas. But this time, Lilly wants to be first.

If a new draft law goes into effect, companies that make or sell fake vaccines could get fines of up to 30 times the value of the goods involved.

On the cusp of FDA approval for its landmark SMA gene therapy Zolgensma, Novartis is investigating an infant's death in a European trial.

Clay Siegall's equity awards skyrocketed to $15.8 million last year from $6.8 million in 2017, pushing his total higher than many a CEO's pay.

BMS investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble arrived two months early.

Amgen lightens the mood in a new TV ad for cholesterol med Repatha even as Amgen continues a patent dispute and price drops for the drug.

The recall from the U.S. of tainted blood pressure medicines reached new heights as India’s Torrent Pharmaceuticals recalled 104 lots of losartan.

What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.